See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $237B | 3.8x | 9.6x | |
| $236B | 3.7x | 8.1x | |
| $130B | 2.5x | 8.3x | |
| $114B | 2.7x | 8.0x | |
| $65.3B | 4.1x | 12.3x | |
| $48.9B | 6.0x | 20.2x | |
| $9.3B | 3.2x | -7.1x | |
| $9.3B | n/a | n/a | |
| $8.7B | 4.8x | -91.6x | |
| $7.2B | 7.6x | 25.9x | |
| $4.8B | 2.3x | -1.3x | |
| $4.8B | 10.8x | 34.2x | |
| $3.7B | 5.5x | 15.0x | |
| $3.6B | n/a | n/a | |
| $3.6B | 11.4x | 71.6x | |
| $2.7B | 6.3x | 20.7x | |
| $2.7B | 6.5x | -77.4x | |
| $2.6B | n/a | n/a | |
| $2.6B | 2.7x | 7.5x | |
| $2.5B | 7.1x | 26.5x | |
| $2.4B | 24.8x | n/a | |
| $2.0B | 9.4x | -62.9x | |
| $2.0B | 10601.0x | n/a | |
| $1.7B | 7.2x | -4.6x | |
| $1.7B | 10.8x | 11.9x | |
| $1.5B | n/a | n/a | |
| $1.4B | 7.4x | 24.1x | |
| $1.3B | 7.2x | 17.8x | |
| $1.3B | 7.6x | 25.4x | |
| $1.2B | n/a | n/a | |
| $1.1B | 7.7x | 12.8x | |
| $1.1B | 124.5x | -5.1x | |
| $1.1B | 32.3x | -31.9x | |
| $951M | 18.8x | -6.3x | |
| $949M | 242.5x | -3.9x | |
| $923M | 371.4x | -6.3x | |
| $893M | 3.8x | 12.2x | |
| $878M | 2.7x | 68.7x | |
| $878M | 5.6x | 10.6x | |
| $836M | 0.8x | 2.5x | |
| $833M | 4.1x | -23.7x | |
| $779M | 5.1x | -10.4x | |
| $762M | 4.2x | -7.2x | |
| $758M | 4.1x | n/a | |
| $712M | 8.6x | -33.6x | |
| $593M | 8.7x | -3.6x | |
| $581M | n/a | n/a | |
| $537M | n/a | -8.5x | |
| $528M | n/a | n/a | |
| $522M | 5.2x | 23.3x | |
| $503M | 180.9x | -25.7x | |
| $495M | 940.9x | n/a | |
| $470M | 3578.3x | n/a | |
| $452M | 118.6x | n/a | |
| $440M | n/a | n/a | |
| $420M | 1.9x | n/a | |
| $373M | 92.2x | -1.2x | |
| $343M | 1.9x | 8.0x | |
| $319M | 16.2x | -1091.3x | |
| $306M | 341823.2x | -11.7x | |
| $294M | 6.3x | -4.1x | |
| $280M | n/a | n/a | |
| $269M | 222935.9x | -10.7x | |
| $266M | 1.3x | 6.6x | |
| $248M | 11.8x | -0.5x | |
| $241M | 23.0x | -6.4x | |
| $203M | 22.1x | n/a | |
| $199M | 1.1x | n/a | |
| $187M | n/a | -4.5x | |
| $154M | n/a | n/a | |
| $146M | 2.6x | 12.0x | |
| $142M | n/a | n/a | |
| $137M | n/a | n/a | |
| $136M | n/a | n/a | |
| $135M | n/a | n/a | |
| $135M | n/a | n/a | |
| $134M | 37.7x | -8.1x | |
| $120M | n/a | n/a | |
| $119M | n/a | n/a | |
| $118M | n/a | n/a | |
| $115M | n/a | n/a | |
| $108M | n/a | n/a | |
| $97.3M | n/a | n/a | |
| $94.4M | n/a | -0.5x | |
| $92.7M | 22.3x | n/a | |
| $92.2M | 817.9x | n/a | |
| $90.2M | n/a | -4.0x | |
| $89.4M | n/a | -2.6x | |
| $86.5M | 4614.4x | -0.4x | |
| $83.0M | 8.6x | n/a | |
| $81.4M | 0.7x | 4.6x | |
| $77.2M | n/a | -0.5x | |
| $74.0M | 1183.0x | n/a | |
| $73.0M | n/a | n/a | |
| $63.5M | n/a | n/a | |
| $62.8M | 20.8x | -1.7x | |
| $62.5M | 7.3x | n/a | |
| $54.0M | 7.2x | n/a | |
| $49.1M | 7664.7x | -0.2x | |
| $45.0M | 52.2x | -0.8x | |
| $41.9M | n/a | n/a | |
| $36.5M | 4.8x | n/a | |
| $35.6M | n/a | n/a | |
| $35.5M | n/a | -0.4x | |
| $33.8M | 99.1x | n/a | |
| $32.1M | n/a | n/a | |
| $28.5M | n/a | -0.7x | |
| $27.0M | 1734.4x | -0.8x | |
| $26.2M | n/a | n/a | |
| $21.8M | 14.6x | -0.7x | |
| $20.4M | 457.7x | n/a | |
| $15.1M | 52.2x | n/a | |
| $14.7M | 5.4x | n/a | |
| $11.5M | 4.5x | n/a | |
| $10.6M | 9.2x | -0.8x | |
| $6.0M | n/a | n/a | |
| $5.6M | n/a | n/a | |
| $1.4M | 0.4x | -0.1x | |
| -$1.3M | -0.3x | n/a | |
| -$1.8M | n/a | 0.0x | |
| -$3.9M | -1.6x | n/a | |
| -$4.2M | n/a | n/a | |
| -$14.7M | -0.2x | 0.1x | |
| -$15.8M | -2.0x | 0.1x | |
| -$21.1M | -0.3x | 0.1x | |
| -$27.7M | -12.3x | n/a | |
| -$35.7M | n/a | 0.3x | |
| -$45.1M | -1192.9x | n/a | |
| -$49.2M | -0.5x | n/a | |
| -$56.9M | -6.5x | 0.4x | |
| -$71.7M | -2.1x | n/a | |
| -$73.0M | n/a | n/a | |
| -$98.1M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies